JNCE - Jounce Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-81.5M

Cash

189.5M

Avg Qtr Burn

-7.219M

Short % of Float

4.36%

Insider Ownership

15.99%

Institutional Own.

85.33%

Qtr Updated

12/31/22

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
JTX-4014 (Pimivalimab) (PD-1 inhibitor) Details Non-small cell lung carcinoma, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vopratelimab (IgG1 agonist) Details Solid tumor/s, Cancer, Non-small cell lung carcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JTX-8064 (LILRB2/ILT4 Inhibitor) Details Solid tumor/s	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.